Atox Bio Overview
- Year Founded
-
2002
- Status
-
Out of Business
- Employees
-
10
- Latest Deal Type
-
Out of Business
Atox Bio General Information
Description
Developer of novel immunomodulators intended to improve outcomes for serious, unmet medical conditions in the critical care setting. The company treats a rare, life-threatening infection with elevated morbidity and mortality whose results have shown a meaningful improvement across multiple endpoints, enabling healthcare institutions to improve the host's ability to effectively fight the infection and reduce the tissue damage caused to key organs during acute inflammatory situations.
Contact Information
Website
www.atoxbio.comCorporate Office
- 1000 Park Forty Plaza
- Suite 210
- Durham, NC 27713
- United States
Corporate Office
- 1000 Park Forty Plaza
- Suite 210
- Durham, NC 27713
- United States
Atox Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Out of Business | 31-Dec-2019 | Completed | Out of Business | |||
| 6. Later Stage VC (Series F) | 30-Apr-2019 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series E) | 24-Jul-2014 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 19-Dec-2011 | Completed | Generating Revenue | |||
| 3. Angel (individual) | 13-Oct-2010 | Completed | Generating Revenue | |||
| 2. Angel (individual) | Completed | Startup | ||||
| 1. Grant | 01-Apr-2002 | $6.5M | Completed | Startup |
Atox Bio Comparisons
Industry
Financing
Details
Atox Bio Competitors (47)
One of Atox Bio’s 47 competitors is AnTolRx, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Xalud Therapeutics | Venture Capital-Backed | New York, NY | ||||
| Parion Sciences | Venture Capital-Backed | Durham, NC | ||||
| Baliopharm | Venture Capital-Backed | Basel, Switzerland | ||||
| Visterra | Venture Capital-Backed | Waltham, MA |
Atox Bio Patents
Atox Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2014358677-A1 | Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28 | Inactive | 06-Dec-2013 | ||
| AU-2017261479-A1 | Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28 | Active | 06-Dec-2013 | ||
| AU-2017261479-B2 | Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28 | Inactive | 06-Dec-2013 | ||
| CA-2932150-A1 | Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28 | Inactive | 06-Dec-2013 | ||
| EP-3077415-A1 | Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28 | Active | 06-Dec-2013 | C07K14/70521 |
Atox Bio Signals
Atox Bio FAQs
-
When was Atox Bio founded?
Atox Bio was founded in 2002.
-
Where is Atox Bio headquartered?
Atox Bio is headquartered in Durham, NC.
-
What is the size of Atox Bio?
Atox Bio has 10 total employees.
-
What industry is Atox Bio in?
Atox Bio’s primary industry is Drug Discovery.
-
Is Atox Bio a private or public company?
Atox Bio is a Private company.
-
What is Atox Bio’s current revenue?
The current revenue for Atox Bio is .
-
How much funding has Atox Bio raised over time?
Atox Bio has raised $61.4M.
-
Who are Atox Bio’s competitors?
AnTolRx, Xalud Therapeutics, Parion Sciences, Baliopharm, and Visterra are some of the 47 competitors of Atox Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process